內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay)
Endocan
（注：單次混測多因子不超過8個指標 ）
- 編號LMC463Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.01-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.003 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 2621 ¥ 2722 ¥ 2873 ¥ 3074 ¥ 3276 ¥ 3578 ¥ 4032 ¥ 5040 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 78-104 | 87 |
| EDTA plasma(n=5) | 99-105 | 102 |
| heparin plasma(n=5) | 81-89 | 85 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-90% | 88-95% | 80-98% | 88-96% |
| EDTA plasma(n=5) | 94-105% | 98-105% | 95-103% | 93-103% |
| heparin plasma(n=5) | 90-99% | 92-102% | 89-101% | 88-97% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APC463Hu01 | 內(nèi)皮細胞特異分子1(ESM1)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPC463Hu01 | 內(nèi)皮細胞特異分子1(ESM1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC463Hu01 | 內(nèi)皮細胞特異分子1(ESM1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAC463Hu71 | 內(nèi)皮細胞特異分子1(ESM1)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| MAC463Hu22 | 內(nèi)皮細胞特異分子1(ESM1)單克隆抗體 | WB |
| MAC463Hu25 | 內(nèi)皮細胞特異分子1(ESM1)單克隆抗體 | WB |
| SEC463Hu | 內(nèi)皮細胞特異分子1(ESM1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC463Hu | 內(nèi)皮細胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Urology | Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation [PubMed: 22608803] |
| Microvasc Res. | Endocan is useful biomarker of survival and severity in sepsis. [Pubmed: 24769132] |
| J Matern Fetal Neonatal Med. | Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes [Pubmed:25211383] |
| Microvasc Res. | Endocan is useful biomarker of survival and severity in sepsis [Pubmed:24769132] |
| Angiology | Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus [PubMed: 26614790] |
| Archives of Medical Science - Atherosclerotic Diseases | Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study [Journal:-102] |
| Int Immunopharmacol.? | Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. [pubmed:27912147] |
| Oncotarget | Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer [pubmed:28514746] |
| Biomedical and Pharmacology Journal | Changes in Endocan Levels and Blood Coagulation in HIV Infection [DOI: 10.13005/bpj/1082] |
| Life Sciences | A novel role of endocan in alleviating LPS-induced acute lung injury [Pubmed:29627442] |
| International Urology and Nephrology | Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction? [Pubmed:30054863] |
| The Open Rheumatology Journal | Serum Level of Endothelial Cell-Specific Molecule-1 (ESM-1) as a New Potential Biomarker for Rheumatoid Arthritis Disease Activity [Doi: 10.2174/1874312901812010189] |
| Molecular?Medicine?Reports | Downregulation of ENDOCAN in myeloid leukemia cells inhibits proliferation and promotes apoptosis by suppressing nuclear factor?κB activity [Pubmed: 30816462] |
| Biomarkers in Medicine | Endothelial biomarkers in the light of new sepsis definition [Pubmed: 30920847] |
| Experimental and Therapeutic Medicine | Risk stratification and prognostic evaluation of endothelial cell?specific molecule1, von Willebrand factor, and a disintegrin?like and metalloprotease with?… [] |
| Turkish Journal of Medical Sciences | A novel marker relationship between carotid intima–media thickness and disease activity score-28 in patients with rheumatoid arthritis: human endothelial cell?… [Pubmed: 31655533] |
| Biomarkers | Role of Ascitic Endocan Levels in the Diagnosis of Spontaneous Bacterial Peritonitis in Decompensated Cirrhosis [Pubmed: 32364003] |
| J Obstet Gynaecol Res | Comparison of the maternal serum endocan levels in preterm premature rupture of membrane and normal pregnancy [34109715] |
| turkish journal clinics laboratory | The relationship between serum endocan levels with the presence of contrast-induced nephropathy in patients undergoing coronary angiography [] |
